Ribosome Recycling as a Drug Target
News Dec 07, 2016
Multidrug-resistant bacteria – strains that have become resistant to conventional antibiotics – pose an increasingly serious medical problem, which underlines the urgent need to develop new antibiotics that attack novel targets. “Many of the most effective antibiotics act by inhibiting various steps in protein synthesis on bacterial ribosomes,” as LMU biochemist Daniel Wilson points out. The search is now on for agents that interfere with aspects of the process that have so far been overlooked in this context. One of these processes is the recycling of stalled ribosomes. Wilson and his research group have just completed a comprehensive structural study of ribosome recycling. The results of the study, which appears in the leading journal Nature, may identify promising points of attack for future antibiotics.
Ribosomes are the organelles that translate the nucleotide sequences encoded in messenger RNA molecules (mRNAs) into the amino-acid sequences of the corresponding proteins. The ribosome “reads” the nucleotide sequence in a fixed direction and is released from the mRNA only when it reaches a defined termination signal. Errors in synthesis or processing may, however, lead to the production of mRNAs that lack termination signals, causing the ribosome to stall while still attached to the mRNA and the growing protein. Cells have evolved several ways of detaching stalled ribosomes from the truncated mRNAs and recycling them for re-use. Wilson’s team has now employed cryo-electron microscopy to determine the structure of the bacterial recycling factor ArfA. Their analysis reveals how ArfA recognizes the stalled ribosome on a defective mRNA and recruits a so-called release factor, which detaches the incomplete protein. This then enables the stalled ribosome to be released from the mRNA in the normal manner by dissociation into its two component subunits. The subunits are then free to interact with another mRNA, thus allowing protein synthesis to proceed.
“Our results could facilitate the development of new antibiotics that act by inhibiting ArfA-mediated ribosome recycling,” says Wilson. Since recycling of human ribosomes is dependent on factors that are unrelated to ArfA, such inhibitors should act specifically on the bacterial ribosome, and kill the bacterial cell by gradually cutting off the supply of free ribosomes.
Story from Ludwig-Maximilians University of Munich. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Huter, P., Müller, C., Beckert, B., Arenz, S., Berninghausen, O., Beckmann, R., & Wilson, D. N. (2016). Structural basis for ArfA–RF2-mediated translation termination on mRNAs lacking stop codons. Nature. doi:10.1038/nature20821
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018